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Summary We investigated the combined effect of radiation and clinically relevant doses of emitefur (BOF-
A2), a newly developed anti-cancer agent consisting of a masked form of 5-fluorouracil (5-FU) and a potent
inhibitor of 5-FU degradation, in two types of murine tumours. In preliminary pharmacokinetic studies, the
area under the curve for 5-FU in plasma, after administration of 12.5 mg kg-1 and 25 mg kg-1 emitefur in
mice, appeared to be similar to that obtained on the first day and that on the seventh day, respectively, after
starting administration of 400-600 mg day 'in humans. These doses (12.5 and 25 mg kg-1) of emitefur were
evaluated either alone or in combination with single (15 Gy), five-fraction (4 Gy each) or ten-fraction (2.8 Gy
each) irradiation using a tumour growth delay assay for SCCVII tumours and in combination with four-
fraction (5 Gy each) irradiation using an in vivo -in vitro assay for EMT6 tumours. The anti-tumour and
radiation-enhancing effects of 12.5 mg kg-' emitefur were not significant in any except the ten-fraction
experiment. On the other hand, multiple doses of 25 mg kg-' emitefur given either alone or in combination
with radiation produced marked effects. The mean tumour growth delay time (the time to double in volume for
treated tumours minus that for untreated tumours) was 8.1 days for five administrations of 25 mg kg-'
emitefur, 10.4 days for five fractions of4 Gy and 22.1 days for five treatments with the combination of the two.
Thus, the increase in growth delay afforded by this combination was at least additive. The effect of four
fractions of 5 Gy with 25 mg kg-
1 emitefur in EMT6 tumours was lower than that of four fractions of 7.5 Gy,
but the effect offive fractions of4 Gy with this dose of emitefur in SCCVII tumours was similar to the effect of
five fractions of 6 Gy, and the effect of ten fractions of 2.8 Gy with 25 mg kg- emitefur was much higher than
that of ten fractions of 4.2 Gy. In conclusion, emitefur given either alone or in combination with radiation
appears to have a significant anti-tumour effect even at clinically relevant dose levels, although a threshold dose
exists between 12.5 and 25 mg kg-'. Further clinical studies of this compound are warranted.
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Emitefur (BOF-A2, Figure 1) is a newly developed anti-
cancer agent which consists of 1-ethoxymethyl-5-fluorouracil
(EM-FU) and 3-cyano-2,6-dihydroxypyridine (CNDP) (Fujii
et al., 1989; Hirohashi et al., 1993). EM-FU is a masked form
of 5-fluorouracil (5-FU) and is gradually converted to 5-FU
in the microsomal fraction of the liver; CNDP is a potent
inhibitor of 5-FU degradation (Tatsumi et al., 1993; Okayasu
et al., 1994). In vivo, emitefur is catabolised into EM-FU and
CNDP, and high concentrations of 5-FU are maintained for
much longer periods than after administration of 5-FU itself
(Miyauchi et al., 1994). In addition, CNDP inhibits
production of fluoro-fl-alanine, a toxic metabolite of 5-FU,
and hence reduced neurotoxicity and cardiotoxicity may be
expected (Harada et al., 1993). Considering these favourable
characteristics together with its oral formulation, emitefur
may substitute for continuous intravenous infusion of 5-FU
in future. Preclinical laboratory studies have demonstrated
the high anti-tumour activity of emitefur in various
experimental tumour systems (Fujii et al., 1989; Shirasaka
et al., 1990). Late phase II clinical studies have already been
completed (Nakai et al., 1994), and it is anticipated that this
drug will be approved as a new anti-cancer agent in Japan in
the near future. Also, clinical development of emitefur is
under consideration in both Europe and the United States.
Since the radiation-potentiating effect of 5-FU has been
established in both laboratory (Weinberg and Rauth, 1987;
Lawrence and Maybaum, 1993; Buchholz et al., 1995) and
clinical (Moertel et al., 1981; Sanchiz et al., 1990) studies, it is
likely that this compound will be combined with radiation
therapy in clinics.
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In our previous study (Murata et al., 1996), we
investigated the combined effect of emitefur and mainly
single radiation in murine SCCVII tumours and found that
the combined effect was marked and nearly additive at drug
doses of 30- 150 mg kg-'. However, these doses are higher
than can be used in humans, and it was not clarified how
great a combined effect could be expected in clinics. In this
study, therefore, we investigated the effect of clinically
relevant doses of emitefur combined with radiation in two
types of murine tumours. From the previous results of
pharmacokinetic studies in both mice and humans (Shirasaka
et al., 1990; Sakata et al., 1995), we deduced that the
clinically relevant dose of emitefur is between 12.5 and
25 mg kg-' in mice.
Materials and methods
Animals and tumours
The SCCVII carcinoma of C3H/He mice was used for
tumour growth delay assay, and the EMT6 sarcoma of
Balb/c mice was used for in vivo-in vitro colony assay. The
characteristics of these tumours were described previously
(Shibamoto et al., 1986). The mice were all female and 10
weeks old at the start of treatment. Exponentially growing
cells cultured in Eagle's minimum essential medium
supplemented with 12.5% fetal bovine serum were inocu-
lated subcutaneously into the right hind leg (SCCVII) or both
legs (EMT6) of mice. The growth delay assay was performed
when the SCCVII tumour reached 9 mm in average diameter,
and the in vivo in vitro assay was performed when the EMT6
sarcoma reached 10 mm in diameter (10-11 days after
inoculation in both tumour types).060- Emitefur and radiation
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Drugs
Emitefur was provided by Otsuka Pharmaceutical (Tokyo,
Japan). The drug, suspended in 1% hydroxypropylmethyl
cellulose, was given per os at a volume of 0.01 ml g-'. We
administered emitefur 1 h before irradiation, in accordance
with the previous study in which the timing of emitefur
administration was found to have no influence on the
combined effect (Murata et al., 1996). We confirmed that
the vehicle has no influence on tumour growth or response
when given up to ten times alone or 1 h before irradiation.
Therefore, the control and radiation-alone groups ofmice did
not receive the vehicle.
Irradiation
Irradiation was carried out using a cobalt-60 source at a dose
rate of 1.3 Gy min- . For the growth delay assay, mice were
given local irradiation without anaesthesia using the method
described by Shibamoto et al. (1987). For the in vivo-in vitro
assay, the mice were given whole-body irradiation without
anaesthesia or physical restraint.
Tumour growth delay assay
Emitefur (12.5 and 25 mg kg-') was given one, five, or ten
times alone or combined with each fraction of the following
radiation regimens: single irradiation with 15 Gy; five
fractions of 4 Gy each delivered every day over 5 days; and
ten fractions of 2.8 Gy each given every day over 10 days.
The three dimensions of each tumour were measured every
other day with calipers, and the tumour volume was
estimated using the formula t/6 x product of the three
dimensions. All mice were weighed on the first and seventh
days of treatment and if the experiments had not yet been
terminated, also on the 11th and 15th days. The net body
weight was estimated by subtracting tumour weight, which
was calculated as 1 g x tumour volume (cm3). The mean net
weight of all mice was 21.7 g at the start of the experiments.
The tumour growth time (TGT) was defined as the time
required after the first day of treatment for a tumour to reach
twice the initial volume, and the tumour growth delay time
(TGDT) was defined as the TGT in each treated mouse
minus the mean TGT in the control group. Differences in
TGT or TGDT values between pairs of treatment groups
were examined by Student's or Welch's t-test.
In vivo -in vitro colony assay
Emitefur (12.5 and 25 mg kg-') was given four times, alone
or combined with four fractions of 5 Gy each given at 12 h
intervals over 36 h. For comparison, one group of mice
received four fractions of 7.5 Gy. After the last irradiation,
tumour-bearing mice were kept alive for 8 h to allow full
repair of potentially lethal damage (Shibamoto et al., 1985)
and to reduce the drug levels in tumour tissue. Then, the
tumours were excised, minced with scissors and treated with
0.1% neutral protease solution for 40 min according to the
procedure described by Shibamoto et al. (1986). After
counting of viable cells, appropriate numbers of cells were
plated onto dishes and cultured for 10 days with the medium
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Figure 1 Chemical structure of emitefur. EM-FU, -ethoxy-
methyl-5-fluorouracil; CNDP, 3-cyano-2,6-dihydroxypyridine.
described above. The colonies were then fixed, stained and
counted. Three tumours were used for each determination.
The control plating efficiency was 29+4% (s.d.), and all the
surviving fractions were corrected by this value.
Pharmacokinetic study
To determine whether the drug doses used in this study are
equivalent to those used in humans, the concentrations of 5-
FU in the plasma of the C3H/He mice were determined after
administration of emitefur (12.5 and 25 mg kg-') using the
gas chromatography-mass spectrometer procedure (Miyau-
chi et al., 1996). At various intervals after drug administra-
tion, blood was collected through the inferior vena cava and
centrifuged at 3000 r.p.m. for 10 min. Distilled water (2 ml)
containing 0.1 ig of internal standard (1,3-bis-'5N-5-FU),
50 il of SN hydrochloric acid and 40 ml of chloroform-
methanol (50:1) was added to 250 pl of plasma and shaken.
To the aqueous phase, 40 ml of ethyl acetate was added to
extract 5-FU. The organic phase was evaporated to dryness
under a stream of nitrogen gas. Silation of the 5-FU was
performed as follows: a mixture of 1 ml of N,O-bis-
(trimethylsilyl) trifluoroacetamide, 1 ml of pyridine and
2 ml of toluene was added to the test tube and heated for
20 min at 80°C. The ion peak (M/Z= 274.4, 276.4)
corresponding to the molecular ion peak of silylated 5-FU
or silylated internal standard was monitored by gas
chromatography - mass spectrometry.
Results
Tumour growth delay assay
The TGDT values for the single-, five- and ten-fraction
experiments are shown in Table I. Single doses of emitefur
(12.5 and 25 mg kg-') given alone did not produce any
significant anti-tumour effect, nor did the drug combined
with single 15 Gy irradiation produce any significant
elongation of TGDT compared with that of 15 Gy alone,
although 25 mg kg-' emitefur produced slight elongation.
In contrast, five doses of 25 mg kg-' emitefur given over 5
days alone had a significant anti-tumour effect (Figure 2). In
addition, when this dose of emitefur was combined with five
fractions of 4 Gy irradiation, a striking combined effect,
Table I Tumour growth delay time (TGDT)
TGDT (days)
Treatment Mean s.e.
Single treatment
Emitefur (12.5mgk- ) 0.0 0.6
Emitefur (25mgkg- ) -0.1 0.4
15Gy 10.1 1.6
20Gy 12.2 1.8
Emitefur (12.5mgk) + 15Gy 10.0 1.4
Emitefur (25mgkg )+ 15Gy 12.1 1.4
Five treatments
Emitefur (I2.5mgk- ) 1.0 0.5
Emitefur (25mgkg- ) 8.1 0.7
4Gy 10.4 1.6
6Gy 22.4 2.8
Emitefur (12.5mgk- )+4Gy 9.9 1.0
Emitefur (25mgkg- )+4Gy 22.1 2.5
Ten treatments
Emitefur (12.5mgk- ) 2.8 0.7
Emitefur (25 mgkg- ) 23.3 1.7
2.8Gy 9.6 0.9
4.2Gy 22.0 1.3
Emitefur (12.5mgk ')+2.8Gy 11.7 1.4
Emitefur (25mgkg- ) +2.8Gy > 39.6a
aIn this group, four of the ten mice were cured, and for these mice
the maximum observed TGDT was allocated to estimate a minimum
value for TGDT.
0
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c-which was equivalent to the effect of five fractions at 6 Gy,
was observed. The effect of the emitefur was observed shortly
after the treatment, which contrasted with the delayed
manifestation of the radiation effect. On the other hand,
the anti-tumour effect of five doses of 12.5 mg kg-' emitefur
was insignificant and, even when combined with five fractions
of 4 Gy, the combined effect was similar to the effect of
radiation alone.
The effect of 25 mg kg-' emitefur was more marked when
it was given ten times, either alone or before each fraction of
2.8 Gy given ten times (Figure 3). The effect of emitefur
alone at this dose was equivalent to that of ten fractions at
4.2Gy. The combined effect was still greater, and four of ten
mice receiving ten fractions of 25 mg kg-' emitefur plus
2.8 Gy irradiation were cured of their tumours. Ten
administrations of emitefur (12.5 mg kg-') alone also
produced modest prolongation of TGT compared with no
treatment (P=0.015), but when it was combined with ten
fractions of 2.8 Gy the combined effect was not significantly
higher than the effect of radiation alone (P=0.24).
Changes in the net body weight of mice
The groups of mice receiving single or five treatments with
radiation and/or emitefur showed no significant body weight
loss. Also, the mice receiving ten treatments with
12.5 mg kg-' emitefur and/or radiation did not lose weight.
The weight of the mice receiving ten treatments with
25 mg kg-' emitefur with and without irradiation was
similar to their pretreatment level on the seventh day but,
on the 11th day, the weight was 96.5%+0.8% (s.e.) of the
pretreatment level for the former group and 94.2+1.4% for
the latter. On the 15th day, however, the weight of these two
groups recovered to 104.2-+-1.2% and 107.6+1.5% respec-
tively.
In vivo-in vitro assay
Figure 4 shows surviving fractions for EMT6 cells after four
treatments with emitefur alone or in combination with four
fractions of 5 Gy given at 12 h intervals. With this treatment
schedule, emitefur had a modest anti-tumour effect at
25 mg kg-' but no effect at 12.5 mg kg-'. The combined
effect of emitefur and radiation was marked at 25 mg kg-'
but insignificant at 12.5 mg kg-' (P=0.22) compared with
Emitefur and radiation
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the effect of radiation alone. However, the combined effect
obtained with four fractions of 5 Gy plus 25 mg kg-'
emitefur did not exceed the effect of four fractions of
irradiation at 7.5 Gy. The mean cell survival after four
treatments with 25 mg kg-' emitefur and 5 Gy (0.0018) was
12% of the expected level derived from the product of the
mean cell survival after the drug treatments alone (0.56) and
that after four fractions of 5 Gy (0.027).
5-FU levels in plasma
Figure 5 shows the 5-FU concentrations in the plasma of
C3H mice after oral adminisitration of emitefur. The 5-FU
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Figure 3 Growth curves for SCCVII tumours after ten
treatments with radiation and/or emitefur. 0, Control; A,
emitefur 12.5mgkg- x 10; 1, emitefur 25mgkg-1 x lO; 0,
2.8Gyx 10; A, (emitefur 12.5mgkg-1+2.8Gy)x 10; *, (emi-
tefur 25mgkg-1+2.8Gy)x lO; X, 4.2Gyx 10. Treatment was
started on day 0. Each point represents the mean for 1O- I1 mice.
Error bars are omitted for clarity.
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Figure 2 Growth curves for SCCVII tumours after five
treatments with radiation and/or emitefur. 0, Control; A,
emitefur 12.5mgkg- x5; OL, emitefur 25mgkg-lx5; 0,
4Gy x 5; A, (emitefur 12.5mgkg- +4Gy) x 5; *, (emitefur
25mgkg- '+4Gy) x 5; X, 6Gy x 5. Treatment was started on
day 0. Each point represents the mean for 9-10 mice. Error bars
are omitted for clarity.
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Figure 4 Surviving fraction for EMT6 tumour cells after four
treatments with radiation and/or emitefur (Emi). A, Emitefur
12.5mgkg- ' x 4; El, emitefur 25mgkg- ' x 4; 0, 5Gy x 4; A,
(emitefur 12.5mgkg- 1 + 5Gy) x 4; *, (emitefur 25mg
kg- + 5Gy) x 4; X, 7.5 Gy x 4. All surviving fractions were
corrected by the control plating efficiency (29%). Each point
and error bars represent the mean+s.d. of four determinations.
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Figure 5 Concentrations of 5-FU in plasma of C3H mice after
oral administration of emitefur (A, 12.5mgkg-; C],
25mgkg-1). Each point and error bars represent the
mean+s.d. for three mice.
level decreased gradually after emitefur administration. The
pharmacokinetic parameters calculated are shown in Table II.
Discussion
In a clinical pharmacokinetic study in which 100 mg m-2 of
emitefur was administered twice daily for two weeks, the
mean area under the curve (AUC) and peak concentration
(Cmax) for 5-FU in plasma was 480 ng h ml-' and
36 ng ml-', respectively, on the first day but 1260
ng h ml-' and 82 ng ml-', respectively, on the seventh day
(Sakata et al., 1995). In future clinical studies, 200 mg of
emitefur (130- 140 mg m-2 according to the Japanese
standard) will be given twice daily and the AUC for 5-FU
is expected to be 600-700 ng h ml-' on the day of starting
administration and 1600-1800 ng h ml- ' after 1 week.
Previous pharmacokinetic studies revealed that the AUC
for 5-FU was 1850 ng h ml-' in nude mice after administra-
tion of emitefur at 25 mg kg-' and 1220 ng h ml-' after
17.5 mg kg-' (Shirasaka et al., 1990). In the C3H/He mice
examined in this study, the AUC and Cmax was 926 ng h ml-l
and 436 ng ml-', respectively, after administration of
12.5 mg kg-' emitefur and 2140 ng h ml-' and
894 ng ml-', respectively, after administration of
25 mg kg-'. Therefore, the AUC for the dose of
12.5 mg kg-' in mice is considered to be slightly higher
than that in humans on the first day at an initial dose of
400 mg day-', and the AUC for 25 mg kg-' is considered to
be slightly higher than that in humans on the seventh day.
These AUC values in mice, however, may be similar to those
in humans if 200 mg of emitefur is given three times per day,
which is another possible option of administration. The Cmax
is thought to be about 10-fold higher in mice than in humans,
but the AUC is considered to be more relevant than the Cmax
to estimate the efficacy of emitefur. Hillcoat et al. (1978)
reported that the AUC value was correlated with clinical
response in colon cancer patients treated with 5-FU infusion.
Also, continuous intravenous infusion of 5-FU is known to
be more effective than bolus injection (Seifert et al., 1975;
Lokich et al., 1989), although the Cmax is about 100-fold
lower for continuous infusion than for bolus injection (Fraile
et al., 1980). Therefore, the results of this study seem to be
applicable to the prediction of the likely efficacy of emitefur
in the clinic.
Of the drug doses used in this study, ten doses of
12.5 mg kg-' emitefur given alone produced only a small
growth delay of SCCVII tumours, and when it was combined
with ten fractions of 2.8 Gy the combined effect was not
significantly higher than the effect of radiation alone. Fewer
Table II Pharmacokinetic parameters of 5-FU in plasma after
single administration of emitefur to C3H mice
Dose T.ax Cmax Half-life AUC (nghml-)
(mgkg-) (min) (ngml) (min) 0-2h 0-8h
12.5 30 436 57 598 926
25 30 894 62 1320 2140
Tmax, time to maximum concentration; Cmax, maximum concentra-
tion; AUC, area under the curve. Half-lives were calculated by the
least-squares method, and AUC values were calculated by a
trapezoidal rule.
treatments with 12.5 mg kg-' emitefur did not produce any
significant tumour growth delay. On the other hand, multiple
doses of 25 mg kg-' emitefur, when given either alone or in
combination with fractionated irradiation, had a pronounced
effect. The groups of mice receiving ten treatments with
25 mg kg-' emitefur with or without radiation had a slight
weight loss on the 11th day, but it was only temporary. Thus,
the contribution to growth delay from debilitation of the
mice as a result of drug toxicity seems to be minimal. In our
previous study, the combined effect of emitefur
(>30 mg kg-') and radiation on the growth delay of
SCCVII tumours appeared to be nearly additive (Murata et
al., 1996). In the present study also, 25 mg kg-' emitefur and
radiation produced at least an additive tumour response in
the five-fraction experiment, since the TGDT in the combined
group (22.1 +2.5 days) was similar to the sum of the TGDT
in the radiation group (10.4+1.6 days) and that in the
emitefur group (8.1 +0.7 days). With ten treatments, the
increase in growth delay was possibly more than additive.
In the in vivo-in vitro colony assay of EMT6 tumours, the
effect of emitefur was insignificant at 12.5 mg kg-', as in the
growth delay experiment. At 25 mg kg-', the combined effect
with radiation was marked and possibly more than additive,
but the effect of emitefur alone was not as marked as the
result of the five-fraction growth delay experiment. Such
discrepancies between the results of the two assays may be
partly due to the tumour types and numbers of treatments,
but they may also be due to the assay. As shown in Figures 2
and 3, the effect ofemitefur was manifested immediately after
administration, which was in marked contrast with the
delayed effect of radiation. In this assay, the tumours were
excised about 44 h after the first irradiation, and it is possible
that the effect of the first (and possibly second) dose of
emitefur was not reflected in the result. We used this
particular assay because EMT6 tumours are not suitable
for the growth delay assay because of their immunogenicity;
however, growth delay assay with non-immunogenic tumours
may better demonstrate the overall effect of anti-cancer
agents such as emitefur.
This series of experiments demonstrated that emitefur is
effective at clinically relevant dose levels and that a threshold
dose for its efficacy exists between 12.5 and 25 mg kg-'.
Because of the great difference in effect between these two
doses, pharmacokinetic monitoring is recommended in
clinical studies. As the AUC for 5-FU in humans shortly
after starting emitefur administration may be similar to that
obtained with 12.5 mg kg-' emitefur in mice, the clinical
efficacy may not be expected to manifest at such an early
period. However, reasonable anti-tumour and radiation-
enhancing effects may be expected after several days of
emitefur administration, when the 5-FU AUC has reached
higher levels.
This study also disclosed that the effect of emitefur
becomes greater with increasing number of emitefur
treatments. In the next clinical studies, 200 mg of emitefur
will be given twice daily for 2 weeks, after which the drug will
be discontinued for 2 weeks to allow recovery from
myelosuppression, and then the cycle will be repeated. From
the results of our study, we expect that such administration
for 14 consecutive days will be more effective than fewer
treatments during a cycle.Emitefur and radiation
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In summary, emitefur seems to be quite an effective anti-
cancer and radiation-potentiating agent, even at doses that
seem to be clinically relevant. The interaction between
emitefur and radiation seems to be at least additive. Further
clinical evaluation is warranted.
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